Group-wide research and development costs rose by 3.9% to € 2,521 million in 2022 (2021: € 2,426 million) and led to a research spending ratio (research and development costs as a percentage of net sales) of 11.3% (2021: 12.3%). Accounting for a 70% (2021: 73%)...
Merck Group Women in leadership positions 38 % Diversity and inclusion Greenhouse gas emissions (Scope 1 and 2) -10 % Climate action Important topics about icon Management Report About MeRck shares icon To Our Shareholders MeRck Shares history icon Management Report Overview 2022 strategy...
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the company’s other filings with the Securities and Exchange Commission (...
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (...
Q4 FY 2022 Online Report Annual Report (PDF) Single Entity Report Merck KGaA, Darmstadt, Germany Online Sustainability Report 2022 incl. SASB and TCFD report Sustainability Report (PDF) 2022 incl. SASB + TCFD Earnings Presentation Financial Statement (XLS) Financial Statement (PDF) Regional Sector...
Report About the Group shares icon To Our Shareholders Our Shares history icon Management Report Overview 2022 strategy icon Management Report Strategy development icon Management Report Research and Development sustainability icon Management Report Non-financial Statement forecast icon Management Report Forecast...
December 16, 2024 · 2 min read · Tristan Manalac Deals Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters December 13, 2024 · 1 min read · Annalee Armstrong Drug pricing Drug Price Watchdog Calls Out Five Pharmas for Unjustified Price Hikes ...
future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the...
’s top product but also one of the best-selling drugs worldwide, generating some 25 billion U.S. dollars in revenue during 2023. The cancer drug with the generic name pembrolizumab increased its revenues for around four billion U.S. dollars compared to 2022. Another of Merck’s top ...
Merck & Co. MORE ON THIS TOPIC Huntington’s disease Novartis Pays Up to $2.9B in Huntington’s Deal With PTC December 2, 2024 · 2 min read · Tristan Manalac Gene therapy Bluebird’s Gene Therapy Skysona...